Slack Technologies (NYSE:WORK) Gains Momentum After A Bullish Barron’s Article

Slack Technologies (NYSE:WORK)

On September 30, Slack Technologies Inc. (NYSE:WORK) shares surged 9% after a...

Stay Ahead of the
Stock Market Game!
Subscribe to Small Cap
Exclusive for more


Biotechnology Value Fund is Buying Xoma Corp (NASDAQ...
TWO STOCKS GO UP 109% in Two Trading Days!
Guess Who Picked Up Perrigo Co Plc. (NYSE:PRGO) Shares

On September 30, Slack Technologies Inc. (NYSE:WORK) shares surged 9% after a bullish publication in Barron’s. The publication suggested that the recent weakness of Slack’s stock could chance for investors to buy-in.

Shares jump following bullish publication

In recent months most newly public technology companies have lagged. Investors have growingly been having concerns regarding growth stocks without a definitive path to becoming profitable. According to Barron’s, Slack Technology is unfairly being considered among the growth stocks. The publication quotes some bullish Wall Street market analysts and hedge fund executives pointing to solid engagement as well as the best-in-class partnership platform while at the same time talking down competitive concerns regarding Microsoft Corporation (NASDAQ: MSFT).

Bhavan Suri of William Blair indicated that Microsoft seems to be a fairly incomplete product set relative to Slack in form of functionality. He adds that integrations are significantly minimal. Suri started covering Slack during the summer and gave the stock a buy rating. He was encouraged by the fact that the company already had 645 paying clients generating more than $100,000 each in revenue per year.

Slack Tech went public through a direct listing

Slack Technologies is relatively solid when it comes to its financial position compared to most of its rivals. The company has a strong balance sheet with cash of around $800 million.Slack Tech Chief Executive Officer Stewart Butterfield indicated that the amount of cash they have was the main reason they decided to go public.

The company went public through a direct listing rather than having to go the traditional IPO route. The CEO said that the company didn’t want to raise capital because they already were in a strong financial position and also they were not willing to dilute current shareholders.

Since the company went public its stock has been declining for months and on Friday it closed 43% down from its first trade in June. According to Barron’s publication, the selling activity might be a result of existing stockholders trying to cash out.

Stay in the lopp :

Columbia Wanger Asset Management is Buying Ce...
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Celldex Therapeutics Inc. (NASDAQ:CLDX) reported that Columbia Wanger Asset Management
IMMX Stock Price is so consistent, can it go ...

Immix Biopharma IMMX stock price is down -18% in the last 5 days & volume is up 1559%, but is it

Don't Miss This Bullish Run on OWC Pharmaceut...
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) shares rose 36.57% on Friday to $0.915 and were flat in after-hours trading. Share prices have been trading in

related post

Skip to content